Work Here?
Blueprint Medicines
Work Here?
Biopharma developing kinase inhibitors for cancer
Blueprint Medicines
Work Here?
Biopharma developing kinase inhibitors for cancer
About Blueprint Medicines
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2011
Overview
Blueprint Medicines develops and commercializes kinase inhibitors for cancer and other diseases. Its lead product, Ayvakit (avapritinib), blocks enzymes that drive tumor growth in gastrointestinal stromal tumors with PDGFRA exon 18 mutations. The company also has a pipeline of other kinase inhibitors in clinical development for lung, breast, and blood cancers, plus preclinical programs in immunology and rare diseases. By performing discovery, development, and commercialization in-house, it aims to bring targeted therapies to patients with unmet medical needs and expand its global oncology portfolio.
Simplify's Take
What believers are saying
- Sanofi $9.1B acquisition on June 2, 2025, boosts immunology portfolio and resources.
- AI and machine learning enhance drug discovery productivity since recent integration.
- Targeted protein degradation expansion via 2022 VantAI collaboration diversifies pipeline.
What critics are saying
- Sanofi integration disrupts sales force, eroding Ayvakit market share in 12-18 months.
- FDA black box warnings for Ayvakit hemorrhage drop prescriptions 20-30% in 6-12 months.
- Generic avapritinib from Dr. Reddy's captures 40% GIST market by 2028.
What makes Blueprint Medicines unique
- Ayvakit is the only FDA-approved treatment targeting PDGFRA D842V mutations in GIST.
- PIONEER four-year data confirm AYVAKIT's sustained efficacy in indolent systemic mastocytosis.
- BLU-808 shows wide therapeutic window as first-in-class oral wild-type KIT inhibitor.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$11.6B
Above
Industry Average
Funded Over
6 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Commuter Benefits
Mental Health Support
Employee Stock Purchase Plan
Parental Leave
Stock Price
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 5%2 year growth
↑ 3%Sanofi has acquired the American biotech company Blueprint Medicines, which specializes in systemic mastocytosis, a rare disease characterized by abnormal activation or proliferation of mast cells in tissues, most commonly the skin and bone marrow.
Sanofi is set to acquire Blueprint Medicines for an equity value of $9.1 billion, according to Bloomberg.
Sanofi is acquiring Blueprint Medicines for approximately $9.1 billion, enhancing its immunology portfolio. This acquisition includes Ayvakit, the only FDA-approved treatment for systemic mastocytosis, and promising therapies like elenestinib and BLU-808. Sanofi will finance the deal with cash and new debt, expecting it to boost gross margin and operating income post-2026. The merger aligns with Sanofi's strategy to lead in immunology and address rare diseases.
PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data.
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...
Blueprint Medicines is Hiring for 8 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Blueprint Medicines
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2011
Blueprint Medicines is Hiring for 8 Jobs on Simplify!
Find jobs on Simplify and start your career today